Neoadjuvant Platelet Derived Growth Factor Receptor Inhibitor Therapy Combined With Docetaxel and Androgen Ablation for High Risk Localized Prostate Cancer

Journal of Urology

Volumn 181, Issue 1, 2009, Pages 81-87

  Mathew, Paul ^a   Pisters, Louis L ^a   Wood, Christopher G ^a   Papadopoulos, John N ^a   Williams, Dallas L ^a   Thall, Peter F ^a   Wen, Sijin ^a   Horne, Erin ^a   Oborn, Carol J ^a   Langley, Robert ^a   Fidler, Isaiah J ^a   Pettaway, Curtis A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

docetaxel; imatinib; neoadjuvant therapy; platelet derived growth factor; prostatic neoplasms; receptors

Indexed keywords

ANDROGEN; BICALUTAMIDE; DOCETAXEL; IMATINIB; LEUPRORELIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEHYDRATION; DEPRESSION; DIARRHEA; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EMBOLISM; ERECTILE DYSFUNCTION; EYE DISCHARGE; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HOT FLUSH; HUMAN; HYPERTENSION; INFECTION; LYMPH NODE DISSECTION; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NONCARDIAC CHEST PAIN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN PHOSPHORYLATION; RASH; RISK FACTOR; SIDE EFFECT; THROMBOSIS; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PIPERAZINES; PROSTATIC NEOPLASMS; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RISK FACTORS; SURVIVAL RATE; TAXOIDS;

EID: 57149092363     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.09.006     Document Type: Article

References (20)

1. Heldin C.H., and Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79 (1999) 1283
2. Uehara H., Kim S.J., Karashima T., Shepherd D.L., Fan D., Tsan R., et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 95 (2003) 458
3. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Drucker B.J., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295 (2000) 139
4. Kim S.J., Uehara H., Yazici S., Busby J.E., Nakamura T., He J., et al. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst 98 (2006) 783
5. Gleave M., and Kelly W.K. High-risk localized prostate cancer: a case for early chemotherapy. J Clin Oncol 23 (2005) 8186
6. Pendleton J., Pisters L.L., Nakamura K., Anai S., and Rosser C.J. Neoadjuvant therapy before radical prostatectomy: where have we been?. Where are we going?. Urol Oncol 25 (2007) 11
7. Pietras K., Stumm M., Hubert M., Buchdunger E., Rubin K., Heldin C.H., et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 9 (2003) 3779
8. Pietras K., Rubin K., Sjöblom T., Buchdunger E., Sjöquist M., Heldin C.H., et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62 (2002) 5476
9. Mathew P., Thall P., Bucana C.D., Oh W.K., Morris M.J., Jones D.M., et al. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 13 (2007) 5816
10. Mathew P, Thall P, Wen S, Bucana C, Lin S et al: Platelet-derived growth factor (PDGF) receptor activation status, PDGF ligand kinetics and progression-free survival in men receiving docetaxel for castrate-resistant prostate cancer. Proceedings of the Genitourinary Cancers Symposium 2008; abstract 20246.
11. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 60 (1966) 163
12. Fudge K., Wang C.Y., and Stearns M.E. Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas. Mod Pathol 7 (1994) 549
13. Singh D., Febbo P.G., Ross K., Jackson D.G., Manola J., Ladd C., et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1 (2002) 203
14. Mathew P., Thall P.F., Jones D., Perez C., Bucana C., Troncoso P., et al. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 22 (2004) 3323
15. Prayer-Galetti T., Sacco E., Pagano F., Gardiman M., Cisternino A., Betto G., et al. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int 100 (2007) 274
16. Pettaway C.A., Pisters L.L., Troncoso P., Slaton J., Finn L., Kamoi K., et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 18 (2000) 1050
17. Konety B.R., Eastham J.A., Reuter V.E., Scardino P.T., Donat S.M., Dalbagni G., et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. J Urol 171 (2004) 717
18. Hussain M., Smith D.C., El-Rayes B.F., Du W., Vaishampayan U., Fontana J., et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. Urology 61 (2003) 774
19. Febbo P.G., Richie J.P., George D.J., Loda M., Manola J., Shankar S., et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 11 (2005) 5233
20. Dreicer R., Magi-Galluzzi C., Zhou M., Rothaermel J., Reuther A., Ulchaker J., et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 63 (2004) 1138